Image by Mads Claus Rasmussen / Ritzau Scanpix / AFP via Getty / Futurism
While its customer are shedding pounds, Novo Nordisk, creator of the mega-hit drug Ozempic, is shedding loads of market value amid collapsing sales.
One year ago, the Danish pharmaceutical giant’s market cap exceeded the size of its entire home country’s economy. But this week, it’s continued its steady but drastic decline — which saw its CEO get the axe — by losing nearly $100 billion in value after slashing its sales forecast for the second time this year. Following the…
Source link
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We blogs.grocliq.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at [email protected]
